CorMedix Proprietary Antimicrobial Technology Featured at the ASAPS Aesthetic Meeting 2016
Bedminster, NJ – April 8, 2016 – CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that Z. Paul Lorenc, MD, FACS, a world-renowned board certified aesthetic plastic surgeon on the faculty of Weill-Cornell University Medical College, presented observations gathered from in vitro tests examining the efficacy of suture materials incorporated with CorMedix’s proprietary antimicrobial, taurolidine, against clinically significant microorganisms at the ASAPS Aesthetic Meeting 2016. Dr. Lorenc’s presentation took place on April 7, 2016, as part of the Premier Global Hot Topics session.
Dr. Lorenc’s presentation highlighted research presented earlier this year at the South Beach Symposium, which demonstrated the ability of taurolidine-loaded fibers to inhibit the growth of bacteria located in their vicinity. The study also showed that taurolidine-loaded fibers have the ability to kill major common human pathogens Pseudomonas aeruginosa, Staphylococcus epidermidis, and Staphylococcus aureus. The results suggest that integrating taurolidine into the matrix of a monofilament or multifilament suture could reduce surgical site infections, thereby improving overall patient outcomes.
Dr. Lorenc stated, “The aesthetics industry recognizes the need to safeguard against surgical site infections upon closure with sutures in order to protect the quality of surgeons’ work. The continued interest among aesthetic plastic surgeons in taurolidine’s unique antimicrobial properties further highlights the need in this industry for tolerable and effective post-surgical solutions. Taurolidine, whose antimicrobial properties prevent the micro-organism resistance to which antibiotics are more susceptible, has the potential to be a compelling solution.”
Taurolidine is the active ingredient in CorMedix’s lead product, Neutrolin® an anti-microbial, anti-infective solution for the prevention and treatment of catheter-related blood stream infections. Several Phase 2 studies showed that Neutrolin reduced infection rates by 70 - 100%. Taurolidine is not an antibiotic, and therefore, bacterial resistance against taurolidine has never been observed.
Randy Milby, CorMedix CEO, said, “In the United States alone, between 500,000 and 750,000 surgical site infections occur annually, demonstrating a significant market need. While our focus remains on advancing Neutrolin through clinical studies toward FDA approval, we are highly encouraged by these preliminary findings, which show that Taurolidine may offer benefits not currently available in marketed antimicrobial sutures. We’re currently exploring ways for CorMedix to jointly develop taurolidine-integrated devices, which could result in multiple opportunities to expand our current business.”
About CorMedix Inc.
CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase 3 clinical study of a novel anti-infective solution, Neutrolin, in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.
For Investors & Media:
CorMedix
Maureen McEnroe, CFA: Maureen@machealthcare.com; (914) 588-1873
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: CorMedix’s ability to devote resources to the development of taurolidine for post-surgical solutions and other uses and the risks of clinical development and regulatory approval of any such uses; the cost, timing and results of the planned Phase 3 trials for Neutrolin® in the U.S.; obtaining additional financing to support CorMedix's research and development and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates, including marketing of Neutrolin in countries other than Europe; the risks associated with the launch of Neutrolin in new markets; CorMedix's ability to enter into, execute upon and maintain collaborations with third parties for its development and marketing programs; CorMedix's ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix’s ability to identify and enter into strategic transactions; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
